#USA #Cambridge #Thermo Fisher #genetic medicines #Mirai Bio

Strategic Collaboration between Mirai Bio and Thermo Fisher Scientific

In a significant move poised to reshape the landscape of genetic medicine, Mirai Bio has announced a groundbreaking strategic partnership with Thermo Fisher Scientific. The collaboration aims to merge both companies' capabilities, creating a cohesive platform that enhances the development of genetic therapies and expands access to advanced pharmaceutical services.

Mirai Bio, recognized for its innovative approach to genetic medicine, was founded by Flagship Pioneering. The company's mission is to co-create fully optimized genetic medicines. By leveraging its proprietary machine intelligence-based platform, Mirai enables the high-throughput design and testing of ideal vehicles for tissue-targeted delivery. This technology paves the way for expedient industrialization of development candidates, making it easier to transition concepts into tangible treatments.

Thermo Fisher Scientific stands at the forefront of the life sciences sector, providing a myriad of services related to scientific research and development. Under the newly formed partnership, Thermo Fisher will act as Mirai's preferred contract development and manufacturing organization (CDMO) for current Good Manufacturing Practice (cGMP) services and commercial manufacturing. This affiliation anticipates enhancing Mirai's end-to-end capabilities, allowing for a more seamless integration of service offerings to its partners.

As part of the collaboration, both organizations aim to pool their resources—combining Thermo Fisher’s robust manufacturing capabilities with Mirai’s cutting-edge delivery and optimization technologies. This synergy is expected to accelerate the development timelines of genetic medicines, enabling Mirai to better support its life science partners worldwide in realizing their innovative potential.

Travis Wilson, Executive Chairman of Mirai and Growth Partner at Flagship Pioneering, expressed excitement about the collaboration, stating, "Thermo Fisher is a trusted industry leader with deep technical expertise. Coupling these resources with Mirai's delivery technologies will support accelerated program development for our partners globally. We aim to further bolster Mirai's platform to create targeted, potentially curative programmable medicines."

Vincent Hingot, President of Drug Substance within Pharma Services at Thermo Fisher, emphasized the importance of the partnership, remarking that it serves to eliminate barriers currently inhibiting genetic medicines' potential. He stated, "Our collaboration will integrate our life sciences expertise with Mirai’s machine intelligence-powered platform to help deliver the next generation of medicines to patients in need."

The initial stages of this partnership will utilize Thermo Fisher’s state-of-the-art facility tailored for RNA and Advanced Formulations. Mirai's plans, bolstered by a direct investment from Thermo Fisher as part of their shared initiative, aim to develop transformative capabilities in the burgeoning genetic medicines sector.

Justine Levin-Allerhand, Ph.D., Executive Partner at Flagship and an advocate for this partnership, highlighted the long-standing relationship between the two entities. She remarked, "This partnership exemplifies our combined vision for accelerating the development of new, enabling technologies. By merging Mirai's innovative delivery methods with Thermo Fisher's manufacturing expertise, we maximize the opportunity for co-creating novel therapies that can significantly impact patients' lives."

Mirai Bio's mission transcends mere collaboration; it endeavors to redefine how genetic therapies are conceived, developed, and delivered. With their state-of-the-art platform designed to tackle the inherent limitations of existing genetic medicines—namely, delivery, design, and manufacturing—Mirai is setting the stage for the future of genetic medicine.

For those interested in discovering more about Mirai Bio and the details surrounding this promising partnership, further information can be found on their website or social media platforms. With this powerful alliance, the future of genetic medicine looks promising, unlocking new avenues for research, therapy development, and ultimately, patient care.